Search

Your search keyword '"Wohlschlaeger, Anne"' showing total 13 results
Start Over Author "Wohlschlaeger, Anne"
13 results on '"Wohlschlaeger, Anne"'

2. Unrelated and Haploidentical Peripheral Stem Cell Transplant with Tcrαβ/CD19 Depletion for the Treatment of Pediatric Patients with Inborn Errors of Immunity

Author

McClory, Susan E., primary, Elgarten, Caitlin W., additional, Quijano, Kaitlyn N, additional, Wohlschlaeger, Anne, additional, Hankins, Mrs. Patricia, additional, Wang, Lei, additional, Wang, Yongping, additional, Kadauke, Stephan, additional, Monos, Dimitri, additional, Olson, Timothy S., additional, Grupp, Stephan A., additional, Ochfeld, Elisa, additional, Heimall, Jennifer R., additional, and Bunin, Nancy J., additional

Published
2024
Full Text
View/download PDF

9. A Retrospective Review of Revaccination Patterns in Pediatric Hematopoietic Stem Cell Transplantation Recipients

Author

Wohlschlaeger, Anne, Levy, Ellen, Khan, Raabia N., Heimall, Jennifer, Fisher, Brian T., Metjian, Talene A., Elgarten, Caitlin W., and Freedman, Jason L.

Abstract

Background:After a hematopoietic stem cell transplantation (HSCT), patients are left with little to no immunity to prevent infections. Importantly, this includes immunity gained from previous exposures, including vaccinations. This loss of immunity is a direct result of previous chemotherapy, radiation, and conditioning regimens the patients receive. It is critical to revaccinate patients post-HSCT to ensure protective immunity against vaccine-preventable diseases. Before 2017, all patients at our institution were referred to their pediatrician at approximately 12-month post-HSCT to be revaccinated. Clinical concern was raised at our institution regarding nonadherence and errors in vaccine schedules. Methods:To understand the magnitude of the problem with revaccination, we performed an internal audit of post-vaccine adherence in patients who received an HSCT between 2015 and 2017. A multidisciplinary team was developed to review the audit results and make recommendations. Results:This audit revealed delays in the initiation of the vaccine schedule, incomplete adherence to the recommended revaccination schedule, and errors in administration. Discussion:Based on the review of the data, the multidisciplinary team recommended an approach for systematic assessment of vaccine readiness and centralization of the administration of vaccines to be done within the stem cell transplant outpatient center.

Published
2023
Full Text
View/download PDF

10. Delivering Post Hematopoietic Stem Cell Transplant (HSCT) Vaccines in a Pediatrician's Office Versus Specialty Care Setting

Author

Levy, Ellen, primary, Wohlschlaeger, Anne, additional, Atkinson, Megan, additional, Bunin, Nancy, additional, Elgarten, Caitlin W., additional, Fisher, Brian T., additional, Grupp, Stephan A., additional, Hankins, Patricia, additional, Heimall, Jennifer, additional, Khan, Raabia, additional, Metjian, Talene, additional, Olson, Timothy S., additional, Roberson, Houston, additional, and Freedman, Jason L., additional

Published
2020
Full Text
View/download PDF

11. Atopic dermatitis‐like graft‐versus‐host disease treated with dupilumab.

Author

Larijani, Mary, Zarowin, Diana, Wohlschlaeger, Anne, Perman, Marissa J., and Treat, James R.

Subjects
GRAFT versus host disease, DUPILUMAB, ATOPIC dermatitis, IMMUNOSUPPRESSIVE agents, ITCHING
Abstract

The mainstay of treatment for atopic dermatitis (AD)‐like graft‐versus‐host disease (GVHD) in both pediatric and adult patients includes oral corticosteroids with or without other systemic immunosuppressive therapies. To our knowledge, we report the first case series of dupilumab in the treatment of AD‐like GVHD in a pediatric cohort of four patients, where we observed clinical improvement of GVHD as well as a reduction in itch in 3/4 (75%) patients. Our findings suggest that dupilumab is not only effective in treating AD‐like GVHD, but also reduces systemic immunosuppression in the pediatric transplant population. The ability to reduce the length and amount of immunosuppression as well as improve quality of life suggest that dupilumab may serve as a safe and effective therapeutic option in our transplant population with GVHD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results